Rheumatoid Purpura in Children: a Multicenter Observational Study of Pediatric Emergency Department Management and Follow-up by Primary Care Physicians (PREEMS)

The main objective of this study is to describe the management of children with rheumatoid purpura from admission to the pediatric emergency room to follow-up by primary care physicians after hospital discharge.

Study Overview

• Status: Completed
• Conditions: Rheumatoid Purpura
• Intervention / Treatment: Other: Management of rheumatoid purpura

Detailed Description

Secondary objectives The secondary objective is to assess general practitioners current knowledge and practice of the condition and potential barriers to monitoring and follow-up by general practitioners.

Conduct of research Children diagnosed with rheumatoid purpura within the past 2 years at the 3 participating sites will be included in the study if parental authority holders do not object.

Patients will be identified through the Medical Information Department of each hospital.

Parents will be contacted - first by mail, then by phone - to request permission to collect the child's medical data from medical records, and to retrieve information on the surveillance and follow-up of the disease by general practitioners up to two years after diagnosis.

• Study Type: Observational
• Enrollment (Actual): 66

Contacts and Locations

Study Locations

• France
  • Colmar, France, 68000
    • Hôpitaux civils de Colmar
  • Strasbourg, France, 67200
    • Hôpital de Hautepierre

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 second to 18 years (Child, Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients will be identified by the Medical Information Department of each site. The study will be conducted on patients who have been managed for rheumatoid purpura within the last two years at one of the three participating centers.

Description

Inclusion Criteria:

• Underaged patient diagnosed with rheumatoid purpura during a visit to the pediatric emergencies of Mulhouse, Colmar and Strasbourg
• No objection to the study from the two holders of parental authority

Exclusion Criteria:

- Patient followed in the context of a genetic or malformative pathology, an immune deficiency, or a cancer

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Children diagnosed with rheumatoid purpura at the pediatric emergency department; Children diagnosed with rheumatoid purpura from admission to the pediatric emergency department up to two years of follow-up by general practitioners after hospital discharge.	Other: Management of rheumatoid purpura; Collection of data on the management in pediatric emergency departments (method of diagnosis, complementary examinations, proposed treatment, number of hospitalizations, follow-up after hospital discharge).

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Compliance with the recommendations for the management of rheumatoid purpura	Up to two years after hospital discharge

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Knowledge assessment questionnaire regarding rheumatoid purpura	Evaluation of the knowledge and current practices of general practitioners regarding rheumatoid purpura and identification of the possible obstacles to management and follow-up in primary care, using an online survey	At the beginning of the study

Collaborators and Investigators

• Sponsor: Groupe Hospitalier de la Region de Mulhouse et Sud Alsace

Publications and helpful links

Helpful Links

• Study results

Study record dates

Study Major Dates

• Study Start (Actual): May 9, 2023
• Primary Completion (Actual): July 28, 2023
• Study Completion (Actual): July 28, 2023

Study Registration Dates

• First Submitted: February 10, 2023
• First Submitted That Met QC Criteria: February 10, 2023
• First Posted (Actual): February 21, 2023

Study Record Updates

• Last Update Posted (Actual): November 20, 2025
• Last Update Submitted That Met QC Criteria: November 17, 2025
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Immune System Diseases; Hemorrhage; Skin Manifestations; Hypersensitivity; Hematologic Diseases; Skin Diseases; Blood Coagulation Disorders; Skin Diseases, Vascular; Hemostatic Disorders; Hemorrhagic Disorders; Vasculitis; Purpura; Immune Complex Diseases; Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases; Signs and Symptoms; Hemic and Lymphatic Diseases; IgA Vasculitis
• Other Study ID Numbers: GHRMSA 1278; 2022-A02687-36 (Other Identifier: ANSM)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No